PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22909341-7	2012	Downstream activation of STAT1 upon lipopolysaccharide stimulation was also inhibited by RSVA405.	RSVA405	89-96	signal transducer and activator of transcription 1	Homo sapiens	25-30
25214260-8	2015	RESULTS: Administration of RSVA405 and RSVA314 significantly reduced the serum levels of renal dysfunction and injury markers, including creatinine, blood urea nitrogen, aspartate aminotransferase, and lactate dehydrogenase, compared with vehicle.	RSVA405	27-34	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	170-196
22909341-3	2012	Here, we report that the small-molecule analogs of resveratrol, RSVA314 and RSVA405, are potent inhibitors of STAT3.	RSVA405	76-83	signal transducer and activator of transcription 3	Homo sapiens	110-115
22909341-4	2012	RSVA314 and RSVA405 inhibited both constitutive and stimulated STAT3 activity in HEK293 cells and lipopolysaccharide-stimulated RAW 264.7 macrophages, respectively.	RSVA405	12-19	signal transducer and activator of transcription 3	Homo sapiens	63-68
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	peroxisome proliferator activated receptor gamma	Mus musculus	153-208
22909341-6	2012	We further show that RSVA405 interfered with the inflammatory response by RAW 264.7 cells upon lipopolysaccharide stimulation by inhibiting IkappaB kinase and IkappaBalpha phosphorylation and by decreasing the expression of several cytokines, including the NF-kappaB target genes tumor necrosis factor alpha and interleukin-6.	RSVA405	21-28	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	159-171
22909341-6	2012	We further show that RSVA405 interfered with the inflammatory response by RAW 264.7 cells upon lipopolysaccharide stimulation by inhibiting IkappaB kinase and IkappaBalpha phosphorylation and by decreasing the expression of several cytokines, including the NF-kappaB target genes tumor necrosis factor alpha and interleukin-6.	RSVA405	21-28	interleukin 6	Mus musculus	312-325
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	210-246
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	248-258
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	fatty acid synthase	Mus musculus	261-280
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	fatty acid binding protein 4, adipocyte	Mus musculus	282-310
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	fatty acid binding protein 4, adipocyte	Mus musculus	312-315
21647536-6	2011	RSVA314 and RSVA405 prevented the adipogenesis-dependent transcriptional changes of multiple gene products involved in the adipogenic process, including peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer-binding protein alpha (C/EBPalpha), fatty acid synthase, fatty acid binding protein 4 (aP2), RANTES or resistin.	RSVA405	12-19	chemokine (C-C motif) ligand 5	Mus musculus	318-324
20852062-5	2011	Two of these molecules, RSVA314 and RSVA405, were further characterized and were found to facilitate CaMKKbeta-dependent activation of AMPK, to inhibit mTOR (mammalian target of rapamycin), and to promote autophagy to increase Abeta degradation by the lysosomal system (apparent EC(50) ~ 1 muM).	RSVA405	36-43	mechanistic target of rapamycin kinase	Homo sapiens	152-156
20852062-5	2011	Two of these molecules, RSVA314 and RSVA405, were further characterized and were found to facilitate CaMKKbeta-dependent activation of AMPK, to inhibit mTOR (mammalian target of rapamycin), and to promote autophagy to increase Abeta degradation by the lysosomal system (apparent EC(50) ~ 1 muM).	RSVA405	36-43	mechanistic target of rapamycin kinase	Homo sapiens	158-187
20852062-5	2011	Two of these molecules, RSVA314 and RSVA405, were further characterized and were found to facilitate CaMKKbeta-dependent activation of AMPK, to inhibit mTOR (mammalian target of rapamycin), and to promote autophagy to increase Abeta degradation by the lysosomal system (apparent EC(50) ~ 1 muM).	RSVA405	36-43	latexin	Homo sapiens	290-293